Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 9, 2025, details a material definitive agreement entered into by Catheter Precision, Inc. on May 12, 2025. The Company, incorporated in Delaware and trading on NYSE American under the symbol VTAK, executed a Securities Purchase Agreement with three unaffiliated investors to raise capital and settle existing obligations.
Key Financial Metrics and Transaction Details
The filing does not provide standard operating metrics such as revenue, profit, cash flow, or margins for a specific reporting period. The financial significance of this filing is derived from the capital raise and debt settlement:
- Capital Raised: The Company sold 1.5 million shares of Series B Convertible Preferred Stock with a stated value of $1.5 million.
- Debt Settlement: An additional 1.5 million shares of Series B Convertible Preferred Stock (stated value $1.5 million) were issued to one investor in exchange for senior secured Convertible Promissory Notes of QHSLab, Inc.
- Debt Acquired: The QHSLab Notes acquired have an estimated aggregate principal, interest, and fees of approximately $1.6 million. Both notes are currently in default with uncertain valuation.
- Warrants Issued: Series L warrants were issued to purchase up to 4,285,716 shares of common stock.
- Liquidity Impact: The transaction provides immediate capital and removes the obligation to pay the defaulted QHSLab notes in cash, though it introduces significant potential dilution.
Material Changes and Transaction Structure
The primary material change is the issuance of new equity securities and the assumption of a distressed debt asset. Key structural terms include:
- Conversion Terms: Series B Preferred Stock has a fixed conversion price of $0.35 per share, potentially converting into approximately 2,858 shares of common stock per $1,000 of stated value. Up to 8,574,000 common shares are reserved for conversion.
- Warrant Terms: Series L Warrants have a 5.5-year term, an exercise price of $0.50 per share, and are callable if the 20-day VWAP exceeds $1.50.
- Approval Requirements: Full conversion and warrant exercise require stockholder approval under NYSE American rules. However, up to 2,202,357 shares (19.99% of outstanding common stock) may convert prior to approval if the exchange permits listing.
- Ownership Limits: Beneficial ownership limitations restrict conversion or exercise if the holder would own more than 4.99% (or up to 9.99% at election) of outstanding common stock.
Outlook, Risks, and Contingencies
Management intends to seek stockholder approval for the full conversion and exercise rights at the Annual Meeting of Stockholders on July 25, 2025. The Company has agreed to file a resale registration statement by May 27, 2025.
Risks and Contingencies:
- Valuation Risk: The QHSLab Notes acquired are in default, and there is no assurance they will be paid in full or at all; their valuation is uncertain.
- Dilution Risk: The transaction creates significant potential dilution through the conversion of preferred stock and exercise of warrants.
- Regulatory Risk: The ability to fully convert or exercise warrants is contingent upon stockholder approval and NYSE American listing approvals.
Investor Verification Checklist
- Verify the exact status and recoverability of the $1.6 million QHSLab Notes acquired in exchange for preferred stock.
- Confirm the timeline and likelihood of stockholder approval at the July 25, 2025 Annual Meeting.
- Review the Registration Rights Agreement to understand the timeline for the resale registration statement filing.
- Assess the impact of the 4.99% beneficial ownership limitation on the liquidity of the new securities.
- Monitor the Company's common stock price relative to the $1.50 call price for the Series L Warrants.